Match!
Neil Collinson
Hoffmann-La Roche
Physical therapyGiant cell arteritisTocilizumabPrednisoneMedicine
28Publications
9H-index
695Citations
What is this?
Publications 30
Newest
#2Stanley L. BlockH-Index: 8
Last. Pedro A. Piedra (BCM: Baylor College of Medicine)H-Index: 55
view all 9 authors...
BACKGROUND Baloxavir marboxil (baloxavir) is a novel, cap-dependent endonuclease inhibitor that has previously demonstrated efficacy in the treatment of influenza in adults and adolescents. We assessed the safety and efficacy of baloxavir in otherwise healthy children with acute influenza. METHODS MiniSTONE-2 (Clinicaltrials.gov: NCT03629184) was a double-blind, randomized, active controlled trial enrolling children 1-<12 years old with a clinical diagnosis of influenza. Children were randomized...
Source
#1Leo Yi Yang LeeH-Index: 1
#2Jie Zhou (Imperial College London)
Last. Kenji SatoH-Index: 8
view all 20 authors...
Influenza viruses cause seasonal outbreaks and pose a continuous pandemic threat. Although vaccines are available for influenza control, their efficacy varies each season and a vaccine for a novel pandemic virus manufactured using current technology will not be available fast enough to mitigate the effect of the first pandemic wave. Antivirals can be effective against many different influenza viruses but have not thus far been used extensively for outbreak control. Baloxavir, a recently licensed...
Source
#1John H. Stone (Harvard University)H-Index: 70
#2Katie Tuckwell (Genentech)H-Index: 8
Last. Neil Collinson (Hoffmann-La Roche)H-Index: 9
view all 16 authors...
OBJECTIVE: To evaluate glucocorticoid doses and serological findings in patients with giant cell arteritis (GCA) flares. METHODS: Patients with GCA were randomly assigned to receive double-blind dosing with subcutaneous tocilizumab (TCZ) 162 mg weekly plus 26-week prednisone (TCZ-QW+Pred-26), every-other-week TCZ plus 26-week prednisone (TCZ-Q2W+Pred-26), placebo plus 26-week prednisone (PBO+Pred-26), or placebo plus 52-week prednisone (PBO+Pred-52). Outcomes were prednisone dose, C-reactive pro...
2 CitationsSource
#1John H. Stone (Harvard University)H-Index: 70
#2Katie Tuckwell (Genentech)H-Index: 8
Last. Neil Collinson (Hoffmann-La Roche)H-Index: 9
view all 16 authors...
Source
#1John H. Stone (Harvard University)H-Index: 70
#2Katie Tuckwell (Genentech)H-Index: 8
Last. Neil Collinson (Hoffmann-La Roche)H-Index: 9
view all 16 authors...
Source
#1John H. Stone (VA Boston Healthcare System)H-Index: 1
#1John H. StoneH-Index: 70
Last. Neil CollinsonH-Index: 9
view all 16 authors...
#1John H. Stone (VA Boston Healthcare System)H-Index: 1
#2Katie Tuckwell (Genentech)H-Index: 8
Last. Neil Collinson (Hoffmann-La Roche)H-Index: 9
view all 16 authors...
Source
#1Vibeke Strand (Stanford University)H-Index: 70
#2Sophie Dimonaco (Hoffmann-La Roche)H-Index: 7
Last. John H. Stone (Harvard University)H-Index: 70
view all 6 authors...
Patients with giant cell arteritis (GCA) treated with tocilizumab (TCZ) every week or every other week and prednisone tapering achieved superior rates of sustained remission to patients treated with placebo and prednisone tapering in a randomised controlled trial. Health-related quality of life (HRQOL) in patients from this trial is now reported. Exploratory analyses of SF-36 PCS and MCS and domain scores, PtGA and FACIT-Fatigue were performed in patients treated with weekly subcutaneous TCZ 162...
2 CitationsSource
#1Sara Gale (Genentech)H-Index: 5
#2Huong Trinh (Genentech)H-Index: 1
Last. Shalini V. Mohan (Genentech)H-Index: 2
view all 10 authors...
Introduction The safety profile of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) is well established. TCZ was approved to treat giant cell arteritis (GCA) in 2017 in the USA and Europe, and its safety profile in patients with GCA continues to be defined. The objective of this analysis was to examine incidence rates (IRs) of adverse events of special interest (AESI) occurring during the TCZ clinical development program and in healthcare claims data in patients with GCA or RA.
Source
#1Zdenka Haskova (Genentech)H-Index: 4
#2Vibeke Strand (Stanford University)H-Index: 70
Last. John H. Stone (Harvard University)H-Index: 70
view all 7 authors...
123